182 related articles for article (PubMed ID: 30633621)
1. Comparison of cationic liposome and PAMAM dendrimer for delivery of anti-Plk1 siRNA in breast cancer treatment.
Bulbake U; Kommineni N; Ionov M; Bryszewska M; Khan W
Pharm Dev Technol; 2020 Jan; 25(1):9-19. PubMed ID: 30633621
[TBL] [Abstract][Full Text] [Related]
2. Dendrimer mediated targeting of siRNA against polo-like kinase for the treatment of triple negative breast cancer.
Jain A; Mahira S; Majoral JP; Bryszewska M; Khan W; Ionov M
J Biomed Mater Res A; 2019 Sep; 107(9):1933-1944. PubMed ID: 31008565
[TBL] [Abstract][Full Text] [Related]
3. Design of Cationic Multiwalled Carbon Nanotubes as Efficient siRNA Vectors for Lung Cancer Xenograft Eradication.
Guo C; Al-Jamal WT; Toma FM; Bianco A; Prato M; Al-Jamal KT; Kostarelos K
Bioconjug Chem; 2015 Jul; 26(7):1370-9. PubMed ID: 26036843
[TBL] [Abstract][Full Text] [Related]
4. Dual sensitive and temporally controlled camptothecin prodrug liposomes codelivery of siRNA for high efficiency tumor therapy.
Li Y; Liu R; Yang J; Ma G; Zhang Z; Zhang X
Biomaterials; 2014 Dec; 35(36):9731-45. PubMed ID: 25189519
[TBL] [Abstract][Full Text] [Related]
5. Folate-Mediated Targeted Delivery of siPLK1 by Leucine-Bearing Polyethylenimine.
Hou L; Song Z; Xu Z; Wu Y; Shi W
Int J Nanomedicine; 2020; 15():1397-1408. PubMed ID: 32184594
[TBL] [Abstract][Full Text] [Related]
6. In Vitro and In Vivo Co-delivery of siRNA and Doxorubicin by Folate-PEG-Appended Dendrimer/Glucuronylglucosyl-β-Cyclodextrin Conjugate.
Mohammed AFA; Higashi T; Motoyama K; Ohyama A; Onodera R; Khaled KA; Sarhan HA; Hussein AK; Arima H
AAPS J; 2019 Apr; 21(4):54. PubMed ID: 30993472
[TBL] [Abstract][Full Text] [Related]
7. Cationic Liposome- Multi-Walled Carbon Nanotubes Hybrids for Dual siPLK1 and Doxorubicin Delivery In Vitro.
Pereira S; Lee J; Rubio N; Hassan HA; Suffian IB; Wang JT; Klippstein R; Ballesteros B; Al-Jamal WT; Al-Jamal KT
Pharm Res; 2015 Oct; 32(10):3293-308. PubMed ID: 26085038
[TBL] [Abstract][Full Text] [Related]
8. Anticancer siRNA cocktails as a novel tool to treat cancer cells. Part (A). Mechanisms of interaction.
Ionov M; Lazniewska J; Dzmitruk V; Halets I; Loznikova S; Novopashina D; Apartsin E; Krasheninina O; Venyaminova A; Milowska K; Nowacka O; Gomez-Ramirez R; de la Mata FJ; Majoral JP; Shcharbin D; Bryszewska M
Int J Pharm; 2015 May; 485(1-2):261-9. PubMed ID: 25791760
[TBL] [Abstract][Full Text] [Related]
9. Antibody h-R3-dendrimer mediated siRNA has excellent endosomal escape and tumor targeted delivery ability, and represents efficient siPLK1 silencing and inhibition of cell proliferation, migration and invasion.
Li J; Liu J; Li S; Hao Y; Chen L; Zhang X
Oncotarget; 2016 Mar; 7(12):13782-96. PubMed ID: 26883109
[TBL] [Abstract][Full Text] [Related]
10. Modulated cellular delivery of anti-VEGF siRNA (bevasiranib) by incorporating supramolecular assemblies of hydrophobically modified polyamidoamine dendrimer in stealth liposomes.
Golkar N; Samani SM; Tamaddon AM
Int J Pharm; 2016 Aug; 510(1):30-41. PubMed ID: 27291973
[TBL] [Abstract][Full Text] [Related]
11. The enhancement of siPLK1 penetration across BBB and its anti glioblastoma activity in vivo by magnet and transferrin co-modified nanoparticle.
Liu DZ; Cheng Y; Cai RQ; Wang Bd WW; Cui H; Liu M; Zhang BL; Mei QB; Zhou SY
Nanomedicine; 2018 Apr; 14(3):991-1003. PubMed ID: 29339188
[TBL] [Abstract][Full Text] [Related]
12. Interaction of Cationic Carbosilane Dendrimers and Their siRNA Complexes with MCF-7 Cells.
Białkowska K; Miłowska K; Michlewska S; Sokołowska P; Komorowski P; Lozano-Cruz T; Gomez-Ramirez R; de la Mata FJ; Bryszewska M
Int J Mol Sci; 2021 Jul; 22(13):. PubMed ID: 34281151
[TBL] [Abstract][Full Text] [Related]
13. ScFv-decorated PEG-PLA-based nanoparticles for enhanced siRNA delivery to Her2⁺ breast cancer.
Dou S; Yang XZ; Xiong MH; Sun CY; Yao YD; Zhu YH; Wang J
Adv Healthc Mater; 2014 Nov; 3(11):1792-803. PubMed ID: 24947820
[TBL] [Abstract][Full Text] [Related]
14. Anticancer siRNA cocktails as a novel tool to treat cancer cells. Part (B). Efficiency of pharmacological action.
Dzmitruk V; Szulc A; Shcharbin D; Janaszewska A; Shcharbina N; Lazniewska J; Novopashina D; Buyanova M; Ionov M; Klajnert-Maculewicz B; Gómez-Ramirez R; Mignani S; Majoral JP; Muñoz-Fernández MA; Bryszewska M
Int J Pharm; 2015 May; 485(1-2):288-94. PubMed ID: 25796120
[TBL] [Abstract][Full Text] [Related]
15. Combined Delivery of Temozolomide and siPLK1 Using Targeted Nanoparticles to Enhance Temozolomide Sensitivity in Glioma.
Shi H; Sun S; Xu H; Zhao Z; Han Z; Jia J; Wu D; Lu J; Liu H; Yu R
Int J Nanomedicine; 2020; 15():3347-3362. PubMed ID: 32494134
[TBL] [Abstract][Full Text] [Related]
16. Impact of anti-PLK1 siRNA-containing F3-targeted liposomes on the viability of both cancer and endothelial cells.
Gomes-da-Silva LC; Ramalho JS; Pedroso de Lima MC; Simões S; Moreira JN
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt A):356-64. PubMed ID: 23659854
[TBL] [Abstract][Full Text] [Related]
17. Targeted Treatment of Metastatic Breast Cancer by PLK1 siRNA Delivered by an Antioxidant Nanoparticle Platform.
Morry J; Ngamcherdtrakul W; Gu S; Reda M; Castro DJ; Sangvanich T; Gray JW; Yantasee W
Mol Cancer Ther; 2017 Apr; 16(4):763-772. PubMed ID: 28138033
[TBL] [Abstract][Full Text] [Related]
18. Tumour-specific delivery of siRNA-coupled superparamagnetic iron oxide nanoparticles, targeted against PLK1, stops progression of pancreatic cancer.
Mahajan UM; Teller S; Sendler M; Palankar R; van den Brandt C; Schwaiger T; Kühn JP; Ribback S; Glöckl G; Evert M; Weitschies W; Hosten N; Dombrowski F; Delcea M; Weiss FU; Lerch MM; Mayerle J
Gut; 2016 Nov; 65(11):1838-1849. PubMed ID: 27196585
[TBL] [Abstract][Full Text] [Related]
19. Targeting polo-like kinase 1 enhances radiation efficacy for head-and-neck squamous cell carcinoma.
Gerster K; Shi W; Ng B; Yue S; Ito E; Waldron J; Gilbert R; Liu FF
Int J Radiat Oncol Biol Phys; 2010 May; 77(1):253-60. PubMed ID: 20394857
[TBL] [Abstract][Full Text] [Related]
20. siRNA-mediated integrin-linked kinase suppression: nonspecific effects of siRNA/cationic liposome complexes trigger changes in the expression of phosphorylated-AKT and mTOR independently of ILK silencing.
Verreault M; Bally MB
Oligonucleotides; 2009 Jun; 19(2):129-40. PubMed ID: 19284309
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
